| Title |
[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts
|
|---|---|
| Published in |
PLOS ONE, January 2013
|
| DOI | 10.1371/journal.pone.0053410 |
| Pubmed ID | |
| Authors |
Mette Munk Jensen, Kamille Dumong Erichsen, Camilla Bardram Johnbeck, Fredrik Björkling, Jacob Madsen, Michael Bzorek, Peter Buhl Jensen, Liselotte Højgaard, Maxwell Sehested, Andreas Kjær |
| Abstract |
APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake. |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 5% |
| Belgium | 1 | 5% |
| Unknown | 19 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 24% |
| Student > Ph. D. Student | 5 | 24% |
| Student > Bachelor | 3 | 14% |
| Professor > Associate Professor | 3 | 14% |
| Student > Master | 2 | 10% |
| Other | 0 | 0% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 14% |
| Medicine and Dentistry | 3 | 14% |
| Biochemistry, Genetics and Molecular Biology | 2 | 10% |
| Agricultural and Biological Sciences | 2 | 10% |
| Physics and Astronomy | 2 | 10% |
| Other | 4 | 19% |
| Unknown | 5 | 24% |